Health Canada has granted approval for GlaxoSmithKline’s (GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK announced that Health Canada has approved Ojjaara (momelotinib) for the treatment of splenomegaly and/or disease-related symptoms, in adult patients with intermediate or high-risk primary ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...